Ranbaxy Of India To Close Three Southeast Asia Plants
This article was originally published in PharmAsia News
Executive Summary
India's Ranbaxy Laboratories plans to close three of its Southeast Asia plants, one each in China, Malaysia and Vietnam. The strategy is intended to save the firm about $30 million, according to sources, but Ranbaxy would not comment. The company is said to be seeking buyers for the plants as the firm's first move to sell assets in the wake of its acquisition by Japan's Daiichi Sankyo. The Ranbaxy Guangzhou China plant was the first Sino-Indian partnership across business sectors and the first plant in China to get good manufacturing practices approval. (Click here for more